Interventional × Intestinal Diseases × Gastrointestinal × Clear all
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA
NCT04644315 2023-08-07

ALpha-T

Hoffmann-La Roche

Phase 2 Terminated
1 enrolled 5 charts
NCT01966289 2021-03-30

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
18 enrolled
NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Isofol Medical AB

Phase 1/2 Completed
24 enrolled
NCT01037049 2018-09-17

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Royal Marsden NHS Foundation Trust

Phase 2 Unknown
237 enrolled
NCT01177007 2017-08-28

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

Yale University

Phase 2 Completed
50 enrolled 10 charts